Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.
Reinhard Dummer(University Hospital of Zurich), John T. Lear(Salford Royal Hospital), Karl D. Lewis(University of Colorado Denver), Ragini R. Kudchadkar, Alexander Guminski(The University of Sydney), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Uwe Trefzer(Goethe University Frankfurt), Elizabeth Ruth Plummer, Manisha Mone, Anne Lynn S. Chang(Stanford University), Dalila Sellami(Daiichi Sankyo (United States)), P. Combemale(Centre Léon Bérard), Luc Dirix(European Organisation for Research and Treatment of Cancer), Carmen Loquai(Johannes Gutenberg University Mainz), Tingting Yi(Army Medical University), Martin Kaatz(SRH Wald-Klinikum Gera), Alexander Stratigos(National and Kapodistrian University of Athens), Henry Castro(CytomX Therapeutics (United States)), Michael R. Migden(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k